title: ["A-triple-V" in refractory or relapsed acute myelocytic leukemia].
authors.forename: S
authors.initials: S
authors.lastname: Miyawaki
authors.forename: K
authors.initials: K
authors.lastname: Nemoto
authors.forename: R
authors.initials: R
authors.lastname: Wakamatsu
authors.forename: N
authors.initials: N
authors.lastname: Baba
authors.forename: K
authors.initials: K
authors.lastname: Yashiro
authors.forename: S
authors.initials: S
authors.lastname: Uchida
authors.forename: M
authors.initials: M
authors.lastname: Nakura
authors.forename: M
authors.initials: M
authors.lastname: Karasawa
authors.forename: M
authors.initials: M
authors.lastname: Takada
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; C015019:enocitabine